Epizyme Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Epizyme stock.
View analyst ratings for Epizyme or view top-rated stocks.

Wall Street analysts have given Epizyme a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Epizyme wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Epizyme is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Epizyme.

Epizyme, Inc. (NASDAQ:EPZM) released its earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by $0.13. The biopharmaceutical company had revenue of $7.60 million for the quarter, compared to the consensus estimate of $6.73 million. Epizyme had a negative trailing twelve-month return on equity of 143.20% and a negative net margin of 1,139.03%. The company's quarterly revenue was up 442.9% on a year-over-year basis.
View Epizyme's earnings history.

Epizyme's stock was trading at $18.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EPZM shares have decreased by 51.5% and is now trading at $8.95.
View which stocks have been most impacted by COVID-19.

6 brokerages have issued 12 month price targets for Epizyme's shares. Their forecasts range from $10.00 to $27.00. On average, they anticipate Epizyme's share price to reach $16.33 in the next year. This suggests a possible upside of 82.5% from the stock's current price.
View analysts' price targets for Epizyme or view top-rated stocks among Wall Street analysts.

Some companies that are related to Epizyme include Arvinas (ARVN), Intra-Cellular Therapies (ITCI), Agios Pharmaceuticals (AGIO), Sage Therapeutics (SAGE), Emergent BioSolutions (EBS), Cassava Sciences (SAVA), PTC Therapeutics (PTCT), Nektar Therapeutics (NKTR), Cryoport (CYRX), Dicerna Pharmaceuticals (DRNA), Insmed (INSM), Taro Pharmaceutical Industries (TARO), Pacira BioSciences (PCRX), Rocket Pharmaceuticals (RCKT) and Axsome Therapeutics (AXSM).
View all of EPZM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Pfizer (PFE), Micron Technology (MU), Novavax (NVAX), CRISPR Therapeutics (CRSP), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD) and Dynavax Technologies (DVAX).

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Epizyme's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (14.94%), Redmile Group LLC (8.65%), BlackRock Inc. (8.23%), Palo Alto Investors LP (6.72%), Rock Springs Capital Management LP (2.75%) and Morgan Stanley (1.84%). Company insiders that own Epizyme stock include Carl Goldfischer, David M Mott, Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore and Shefali Agarwal.
View institutional ownership trends for Epizyme.

EPZM stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Redmile Group LLC, Price T Rowe Associates Inc. MD, Allianz Asset Management GmbH, North Star Investment Management Corp., Credit Suisse AG, PDT Partners LLC, and Dimensional Fund Advisors LP. Company insiders that have sold Epizyme company stock in the last year include Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore, and Shefali Agarwal.
View insider buying and selling activity for Epizyme or view top insider-selling stocks.

EPZM stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Wellington Shields Capital Management LLC, Citigroup Inc., Hennion & Walsh Asset Management Inc., Wellington Shields & Co. LLC, Rock Springs Capital Management LP, and Rafferty Asset Management LLC. Company insiders that have bought Epizyme stock in the last two years include Carl Goldfischer, and David M Mott.
View insider buying and selling activity for Epizyme or or view top insider-buying stocks.

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EPZM stock can currently be purchased for approximately $8.95.

Epizyme has a market capitalization of $912.69 million and generates $15.76 million in revenue each year. The biopharmaceutical company earns $-231,690,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.

Epizyme employs 304 workers across the globe.

The official website for Epizyme is www.epizyme.com.

Epizyme is headquartered at 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139.

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]